Sean J. Callahan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sean J. Callahan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Denitza P. Blagev
Intermountain Healthcare, Salt Lake City, United States of America
5 shared publications - Michael J. Lanspa
Intermountain Medical Center
5 shared publications Dixie Harris
Intermountain Medical Center, Murray, Utah
3 shared publications- Colin K. Grissom
Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, USA
2 shared publications Dave S. Collingridge
Department of Research
2 shared publicationsDenitza P. Blagev
University of Utah Health, Salt Lake City, UT; Intermountain Healthcare, Division of Pulmonary & Critical Care Medicine, Salt Lake City, UT
2 shared publications
Latest Publications
- Open Access
- 24 May 2026
- Published by Elsevier in SSRN Electronic Journal
Development of Prediction Models for Mortality and Debility Among Critically Ill Adults Receiving High-flow Nasal Cannula Therapy
ObjectivesThe objective of this study was to examine whether factors known at high-flow nasal cannula (HFNC) initiation could predict inpatient mortality and debility.MethodsMultivariable logistic regression models were developed and evaluated using a secondary data analysis of the Medical Information Mart for Intensive Care database (MIMIC-IV). The cohort consisted of adult patients admitted to Intensive Care Units at Beth Israel Deaconess Medical Center between 2008 and 2019. Patients with a tracheostomy before HFNC use and intubated within 1 hour after HFNC initiation were excluded.ResultsOf the 2,031 patients, 463 (22.8%) died, and 1059 (52.1%) met the composite debility outcome. The final mortality model had an AUC of 0.77 (95% CI: 0.74-0.79). Age, heart rate, blood urea nitrogen (BUN), and need for hemodialysis at HFNC initiation were associated with increased odds of inpatient mortality. The debility model had an AUC of 0.65 (95% CI: 0.63-0.68). Extubation to HFNC therapy increased the odds of debility more than two-fold.ConclusionsA prediction model for inpatient mortality was developed, had good overall performance, and identified age, heart rate, and renal dysfunction as key risk factors. A debility model was also developed, highlighting how patients’ risk profile evolved, but requires further refinement.Implications for Clinical PracticeRisk prediction in patients receiving HFNC therapy should extend past predicting intubation, as other factors lead to mortality, such as concomitant renal dysfunction. Additionally, debility is a common outcome in those receiving HFNC therapy and warrants further study. The ratio of oxygenation (ROX) index performed poorly, in isolation, at predicting mortality and debility.
- 24 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDevelopment of Prediction Models for Mortality and Debility Among Critically Ill Adults Receiving High-flow Nasal Cannula Therapy
ObjectivesThe objective of this study was to examine whether factors known at high-flow nasal cannula (HFNC) initiation could predict inpatient mortality and debility.MethodsMultivariable logistic regression models were developed and evaluated using a secondary data analysis of the Medical Information Mart for Intensive Care database (MIMIC-IV). The cohort consisted of adult patients admitted to Intensive Care Units at Beth Israel Deaconess Medical Center between 2008 and 2019. Patients with a tracheostomy before HFNC use and intubated within 1 hour after HFNC initiation were excluded.ResultsOf the 2,031 patients, 463 (22.8%) died, and 1059 (52.1%) met the composite debility outcome. The final mortality model had an AUC of 0.77 (95% CI: 0.74-0.79). Age, heart rate, blood urea nitrogen (BUN), and need for hemodialysis at HFNC initiation were associated with increased odds of inpatient mortality. The debility model had an AUC of 0.65 (95% CI: 0.63-0.68). Extubation to HFNC therapy increased the odds of debility more than two-fold.ConclusionsA prediction model for inpatient mortality was developed, had good overall performance, and identified age, heart rate, and renal dysfunction as key risk factors. A debility model was also developed, highlighting how patients’ risk profile evolved, but requires further refinement.Implications for Clinical PracticeRisk prediction in patients receiving HFNC therapy should extend past predicting intubation, as other factors lead to mortality, such as concomitant renal dysfunction. Additionally, debility is a common outcome in those receiving HFNC therapy and warrants further study. The ratio of oxygenation (ROX) index performed poorly, in isolation, at predicting mortality and debility.
- 6 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63  (5) , 1012-1017
Multi-modal machine learning classifier for idiopathic pulmonary fibrosis predicts mortality in interstitial lung diseases
- 6 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63  (5) , 1012-1017
Multi-modal machine learning classifier for idiopathic pulmonary fibrosis predicts mortality in interstitial lung diseases
- 1 June 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209  (11) , 1404-1407
Vitamin E Acetate Is Associated with Select Proinflammatory Cytokines: An Analysis of a 2020–2022 Cohort of EVALI Patients
- 1 June 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209  (11) , 1404-1407
Vitamin E Acetate Is Associated with Select Proinflammatory Cytokines: An Analysis of a 2020–2022 Cohort of EVALI Patients
- Open Access
Climate Change for the Pulmonologist
- 1 November 2022
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19  (11) , 1892-1899
Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette– or Vaping-associated Lung Injury
Rationale: E-cigarette– or vaping-associated lung injury (EVALI) was first identified in 2019. The long-term respiratory, cognitive, mood disorder, and vaping behavior outcomes of patients with EVALI remain unknown. Objectives: To determine the long-term respiratory, cognitive, mood disorder, and vaping behavior outcomes of patients with EVALI. Methods: We prospectively enrolled patients with EVALI from two health systems. We assessed outcomes at 1 year after onset of EVALI using validated instruments measuring cognitive function, depression, anxiety, post-traumatic stress, respiratory disability, coronavirus disease (COVID-19) infection, pulmonary function, and vaping behaviors. We used multivariable regression to identify risk factors of post-EVALI vaping behaviors and to identify whether admission to the intensive care unit (ICU) was associated with cognitive, respiratory, or mood symptoms. Results: Seventy-three patients completed 12-month follow-up. Most patients were male (66.7%), young (mean age, 31 ± 11 yr), and White (85%) and did not need admission to the ICU (59%). At 12 months, 39% (25 of 64) had cognitive impairment, whereas 48% (30 of 62) reported respiratory limitations. Mood disorders were common, with 59% (38 of 64) reporting anxiety and/or depression and 62% (39 of 63) having post-traumatic stress. Four (6.4%) of 64 reported a history of COVID-19 infection. Despite the history of EVALI, many people continued to vape. Only 38% (24 of 64) reported quitting all vaping and smoking behaviors. Younger age was associated with reduced vaping behavior after EVALI (odds ratio, 0.93; P = 0.02). ICU admission was not associated with cognitive impairment, dyspnea, or mood symptoms. Conclusions: Patients with EVALI, despite their youth, commonly have significant long-term respiratory disability; cognitive impairment; symptoms of depression, anxiety, post-traumatic stress; and persistent vaping.
- 1 November 2022
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19  (11) , 1892-1899
Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette– or Vaping-associated Lung Injury
Rationale: E-cigarette– or vaping-associated lung injury (EVALI) was first identified in 2019. The long-term respiratory, cognitive, mood disorder, and vaping behavior outcomes of patients with EVALI remain unknown. Objectives: To determine the long-term respiratory, cognitive, mood disorder, and vaping behavior outcomes of patients with EVALI. Methods: We prospectively enrolled patients with EVALI from two health systems. We assessed outcomes at 1 year after onset of EVALI using validated instruments measuring cognitive function, depression, anxiety, post-traumatic stress, respiratory disability, coronavirus disease (COVID-19) infection, pulmonary function, and vaping behaviors. We used multivariable regression to identify risk factors of post-EVALI vaping behaviors and to identify whether admission to the intensive care unit (ICU) was associated with cognitive, respiratory, or mood symptoms. Results: Seventy-three patients completed 12-month follow-up. Most patients were male (66.7%), young (mean age, 31 ± 11 yr), and White (85%) and did not need admission to the ICU (59%). At 12 months, 39% (25 of 64) had cognitive impairment, whereas 48% (30 of 62) reported respiratory limitations. Mood disorders were common, with 59% (38 of 64) reporting anxiety and/or depression and 62% (39 of 63) having post-traumatic stress. Four (6.4%) of 64 reported a history of COVID-19 infection. Despite the history of EVALI, many people continued to vape. Only 38% (24 of 64) reported quitting all vaping and smoking behaviors. Younger age was associated with reduced vaping behavior after EVALI (odds ratio, 0.93; P = 0.02). ICU admission was not associated with cognitive impairment, dyspnea, or mood symptoms. Conclusions: Patients with EVALI, despite their youth, commonly have significant long-term respiratory disability; cognitive impairment; symptoms of depression, anxiety, post-traumatic stress; and persistent vaping.
- Open Access
- 26 May 2021
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 15  (9) , 1089-1091
Is COVID-19 masking the ongoing youth vaping crisis?
E-cigarette, or vaping, product use-associated lung injury (EVALI) is a life-threatening, acute respiratory illness that came to international prominence in 2019 [1,2]. Starting that spring, public...
- 26 May 2021
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 15  (9) , 1089-1091
Open AccessIs COVID-19 masking the ongoing youth vaping crisis?
E-cigarette, or vaping, product use-associated lung injury (EVALI) is a life-threatening, acute respiratory illness that came to international prominence in 2019 [1,2]. Starting that spring, public...
- Open Access
A 64-Year-Old Man With Multifocal Infiltrates